Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coya TherapeuticsCOYA -3.10%49 Market Cap is $102.98 Mil as of Sep. 12, 2026. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued). Among 1,421 Biotechnology companies, Coya Therapeutics ranks worse than 51.79% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Coya Therapeutics's share price for the quarter that ended in Jun. 2026 was $5.85. Coya Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 23.46 Mil. Therefore, Coya Therapeutics's market cap for the quarter that ended in Jun. 2026 was $137.23 Mil.
Coya Therapeutics's quarterly market cap
declined
from Dec. 2025 ($121.42 Mil) to Mar. 2026 ($92.42 Mil) but then
increased
from Mar. 2026 ($92.42 Mil) to Jun. 2026 ($137.23 Mil).
Coya Therapeutics's annual market cap
declined
from Dec. 2023 ($106.74 Mil) to Dec. 2024 ($95.73 Mil) but then
increased
from Dec. 2024 ($95.73 Mil) to Dec. 2025 ($121.42 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Coya Therapeutics's Enterprise Value for Today is $59.80 Mil.
Coya Therapeutics (NAS:COYA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Coya Therapeutics Market Cap Related Terms
Coya Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Coya Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coya Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coya Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Coya Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Coya Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coya Therapeutics (COYA) has a Market Cap of $102.98 Mil as of Sep. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Coya Therapeutics and its competitors. According to the industry distribution chart, Coya Therapeutics ranks #736 out of 1421 companies in the Biotechnology industry, placing it in the top 51.8%.
Is Coya Therapeutics' Market Cap too high?
Coya Therapeutics' current Market Cap is $102.98 Mil. The Biotechnology industry median Market Cap is 118.46. Coya Therapeutics' value of $102.98 Mil is 13.1% below this industry median. Based on the distribution chart, Coya Therapeutics ranks #736 out of 1421 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' Market Cap compare to ONCY and GUTS?
According to the Biotechnology industry distribution chart, Coya Therapeutics ranks #736 out of 1421 companies for Market Cap. This places Coya Therapeutics in the lower half of its industry. The industry median Market Cap is 118.46. Coya Therapeutics' value of $102.98 Mil is 13.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.46, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coya Therapeutics's current Market Cap of $102.98 Mil is 13.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Coya Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 118.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coya Therapeutics's current Market Cap is $102.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current Market Cap is $102.98 Mil and 13.1% below the Biotechnology industry median of 118.46. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current Market Cap is $102.98 Mil as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coya Therapeutics (COYA) Overvalued in 2026?
Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued.
The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54.
GuruFocus considers Coya Therapeutics to be Significantly Undervalued.
Key valuation signals for COYA:
Market Cap: $102.98 Mil
GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
Industry Position: 13.1% below the Biotechnology median (#736 of 1421)
No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score
Get the complete analysis for COYA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COYA has been successfully added to your 
